ALPHA3: A Pivotal Phase 2 Study Evaluating the Safety and Efficacy of First-Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cema- Cel) in Patients With Large B-Cell Lymphoma (LBCL) and Minimal Residual Disease (MRD) After Response to Standard Therapy Meeting Abstract

cited authors

  • Westin, Jason; Burke, John; Lynch, Ryan; Abramson, Jeremy; Stevens, Don; Matasar, Matthew; Fitzgerald, Lindsey; Skarbnik, Alan Zausner; Iragavarapu, Chaitanya; Essell, James; Hunter, Bradley; Merchant, Akil; Varadarajan, Indumathy; Tandra, Anand; Licitra, Edward; Bryan, Locke; Patel, Rushang D.; Behl, Rajesh; Sharmann, Jeff; Holmes, Houston E.; Fanning, Suzanne; Yimer, Habte; Gandhi, Mitul; Simmons, Gary; Feng, Amy; Navale, Lynn; Ghatta, Srinivas; Le Gall, John B.; Herrera, Alex F.

Publication Date

  • September 1, 2024

webpage

published in

category

start page

  • S602

end page

  • S603

volume

  • 24